First-line systemic therapy for hepatocellular carcinoma: new options

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, originating from hepatocytes. HCC ranks as the sixth most frequently diagnosed cancer globally and the third leading cause of cancer-related mortality [1]. The management of HCC requires a comprehensive, multidisciplinary approach, which includes locoregional therapies, surgical intervention, liver transplantation, as well as systemic therapy for advanced forms of the disease. Contemporary, comprehensive management of HCC patients is inconceivable without collaboration with gastroenterologists and infectious disease specialists. For many years, the pharmacological treatment of advanced hepatocellular carcinoma posed a significant challenge in clinical oncology. Due to the rapid advancement of oncological therapeutics, several highly effective first-line treatment options are now available for unresectable and advanced HCC. This article reviews the current approach to selecting first-line treatment regimens for unresectable HCC, with a particular focus on the combination immunotherapy of durvalumab and tremelimumab, which has been incorporated into updated clinical guidelines. Furthermore, the practical experience of two clinics of specialized types of medical care (Oncology) in utilizing the tremelimumab and durvalumab combination in the first-line setting is described.

1. Zheng J., Wang S., Xia L. et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances // Signal Transduction and Targeted Therapy. 2025. Vol. 10, No. 1. P. 35. doi: 10.1038/s41392-024-02075-w.

2. Hwang S.Y., Danpanichkul P., Agopian V. et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment // Clinical and Molecular Hepatology. 2025. Vol. 31, Suppl. S. P. S228–S254. doi: 10.3350/cmh.2024.0824.

3. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2022 году (заболеваемость и смертность). М.: МНИОИ им. П.А.Герцена — филиал ФГБУ «НМИЦ радиологии», 2023. 250 с. [Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2022 (incidence and mortality). Moscow: P.A.Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology, 2023. 250 p. (In Russ.)].

4. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors // Gastroenterology. 2004. Vol. 127, Suppl. S1. P. S35–S50. doi: 10.1053/j.gastro.2004.09.014.

5. Tümen D., Heumann P., Gülow K. et al. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma // Biomedicines. 2022. Vol. 10, No. 12. P. 3202. doi: 10.3390/biomedicines10123202.

6. U.S. Food and Drug Administration (FDA). FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. 2020. Режим доступа: https://www.fda.gov/. Дата обращения: 15.10.2025.

7. Finn R.S., Qin S., Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma // N. Engl. J. Med. 2020. Vol. 382. P. 1894–1905. doi: 10.1056/NEJMoa1915745.

8. Abou-Alfa G.K., Lau G., Kudo M. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma // NEJM Evidence. 2022. Vol. 1, No. 8. Art. EVIDoa2100070. doi: 10.1056/EVIDoa2100070.

9. Rimassa L., Chan S.L., Sangro B. et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC // Journal of Hepatology. 2025. Vol. 83, No. 4. P. 899–908. doi: 10.1016/j.jhep.2025.03.033.

10. Vogel A., Chan S., Furuse J. et al. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study // Ann. Oncol. 2022. Vol. 33. P. S380–S381.

11. Clinical guidelines of the Ministry of Health of the Russian Federation. Liver cancer (hepatocellular), C22.0. Year of approval: 2025. Age category: adults / edited by V.V.Breder et al. Moscow, 2025 (In Russ.)].

12. Fujii Y., Kawaoka T., Shirane Y. et al. First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice // Oncology. 2025. Vol. 103, No. 8. P. 742–747. doi: 10.1159/000541234.

13. Kondili L., Panetta V. et al. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort // Digestive and Liver Disease. 2023. Vol. 55, No. 7. P. 907–917. doi: 10.1016/j.dld.2023.01.004.